Treatment Action Group

Last updated

Treatment Action Group (TAG) is a U.S.-based organization that has been prominent within the movement of HIV/AIDS activism. Being formed in 1991, it has possessed the goals of working with worldwide efforts to increase research on treatments for HIV and for deadly co-infections that affect individuals with HIV, such as hepatitis C and tuberculosis, as well as spur on greater access to and efficient usage of already available treatments. The group additionally monitors research on a possible HIV vaccine and on fundamental science aimed at understanding the pathogenesis of HIV/AIDS.

Contents

History

The Treatment Action Group had its origins in the AIDS activist organization, ACT UP New York. In January 1992, members of the Treatment and Data Committee of ACT UP left the parent group to create a non-profit organization focused on accelerating treatment research. [1] [2]

During the early 1990s, TAG members, including Mark Harrington and Spencer Cox, advocated with government scientists, drug company researchers, and U.S. Food and Drug Administration officials to speed the development of new HIV therapies. [3] The group produced an influential policy report on government investment in basic science, which recommended increasing funding to the National Institutes of Health (NIH) and reorganizing the national AIDS research effort.[ citation needed ]

Following approval of several effective antiretroviral drugs in 1995, Treatment Action Group pressed government and industry to conduct research to understand the long-term effects of the new drugs. [4]

In 2002, TAG began raising awareness of the impact that tuberculosis (TB) was having on people with HIV in the developing world. In 2007, the organization received a $4.7 million grant from the Bill & Melinda Gates Foundation to foster increased international advocacy on TB/HIV research and treatment. [5]

In 2020, Doctors Without Borders stated that that price Cepheid Inc charged for its Xpert Xpress tests was not affordable in countries where people live on less than two dollars a day. They estimated that the cost to Cepheid of providing the test is as low as US$3, and called the offered US$19.80, price profiteering, asking that Cepheid make a more moderate profit by selling the tests for US$5 each. [6] TAG seconded this request, saying that the development of the tests, and their purchase and global deployment, has been done with public funds, while the owners of Cepeid made profits of $3 billion in 2019. They requested the same price reduction for all the tests using the same technique, including COVID-19, HIV, tuberculosis, and Hepatitis C, as the costs are similar regardless of the disease (the tests convert the RNA of the RNA virus into DNA, then tests for the presence of some DNA sequences [7] ). This request started the "Time for $5" campaign. [8]

Mission statement

Treatment Action Group's mission statement describes the group as: “an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS."

TAG works to ensure that all people with HIV receive life saving treatment, care, and information. We are science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions. TAG catalyzes open collective action by all affected communities, scientists, and policymakers to end AIDS. [9]

TAG in the media

TAG's September 1991 demonstration at the home of Senator Jesse Helms was documented in Robert Hilferty's film I Wrapped a Giant Condom Over Jesse Helms' House . [10] [11]

The relationship between TAG and ACT UP is also discussed in the 2012 documentary How to Survive a Plague. [12]

Related Research Articles

<span class="mw-page-title-main">Médecins Sans Frontières</span> International humanitarian medical non-governmental organisation

Médecins Sans Frontières, named Doctors Without Borders in English, is a charity that provides humanitarian medical care. It is a non-governmental organisation (NGO) of French origin known for its projects in conflict zones and in countries affected by endemic diseases. The organisation provides care for diabetes, drug-resistant infections, HIV/AIDS, hepatitis C, tropical and neglected diseases, tuberculosis, vaccines and COVID-19. In 2019, the charity was active in 70 countries with over 35,000 personnel; mostly local doctors, nurses and other medical professionals, logistical experts, water and sanitation engineers, and administrators. Private donors provide about 90% of the organisation's funding, while corporate donations provide the rest, giving MSF an annual budget of approximately US$1.63 billion.

<span class="mw-page-title-main">Tuberculosis</span> Infectious disease

Tuberculosis (TB), also known colloquially as the "white death", or historically as consumption, is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. Tuberculosis generally affects the lungs, but it can also affect other parts of the body. Most infections show no symptoms, in which case it is known as latent tuberculosis. Around 10% of latent infections progress to active disease which, if left untreated, kill about half of those affected. Typical symptoms of active TB are chronic cough with blood-containing mucus, fever, night sweats, and weight loss. Infection of other organs can cause a wide range of symptoms.

The National Institute of Allergy and Infectious Diseases is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Danaher Corporation is an American globally diversified conglomerate founded by brothers Steven and Mitchell Rales in 1984. Headquartered in Washington, D.C., the company designs, manufactures, and markets medical, industrial, and commercial products and services. It has primarily grown by acquisitions, and historically has tried to maintain a very low public profile. Danaher was one of the first companies in North America to adopt the Kaizen principles to manufacturing, which is a lean manufacturing Japanese philosophy of continuous improvement and elimination of waste.

The European and Developing Countries Clinical Trials Partnership (EDCTP) is a partnership between the European Union (EU), Norway, Switzerland and developing countries and other donors, as well as the pharmaceutical industry, to enable clinical trials and the development of new medicines and vaccines against HIV/AIDS, tuberculosis, and malaria. The need for global action against these diseases in order to promote poverty reduction has been recognised by the United Nations, the G8, and the African Union, and the program envisioned the provision of €600 million for the period 2003–2007 in order to translate medical research results into clinical applications relevant to the needs of developing countries.

The Campaign for Access to Essential Medicines is an international campaign started by Médecins Sans Frontières (MSF) to increase the availability of essential medicines in developing countries. MSF often has difficulties treating patients because the medicines required are too expensive or are no longer produced. Sometimes, the only drugs available are highly toxic or ineffective, and they often have to resort to inadequate testing methods to diagnose patients.

<span class="mw-page-title-main">Rifabutin</span> Chemical compound

Rifabutin (Rfb) is an antibiotic used to treat tuberculosis and prevent and treat Mycobacterium avium complex. It is typically only used in those who cannot tolerate rifampin such as people with HIV/AIDS on antiretrovirals. For active tuberculosis it is used with other antimycobacterial medications. For latent tuberculosis it may be used by itself when the exposure was with drug-resistant TB.

Texas Biomedical Research Institute, located in San Antonio, Texas, is an independent, non-profit biomedical research institution, specializing in genetics and in virology and immunology. Texas Biomed is funded by government and corporate grants and contracts, and donations from the public.

<span class="mw-page-title-main">Tuberculous meningitis</span> Medical condition

Tuberculous meningitis, also known as TB meningitis or tubercular meningitis, is a specific type of bacterial meningitis caused by the Mycobacterium tuberculosis infection of the meninges—the system of membranes which envelop the central nervous system.

<span class="mw-page-title-main">Drugs for Neglected Diseases Initiative</span> Non-profit organization

The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness, Chagas disease, malaria, filarial diseases, mycetoma, paediatric HIV, cryptococcal meningitis, hepatitis C, and dengue. DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.

<span class="mw-page-title-main">Unitaid</span> Global health initiative

Unitaid is a global health initiative that works with partners to bring about innovations to prevent, diagnose and treat major diseases in low- and middle-income countries, with an emphasis on tuberculosis, malaria, and HIV/AIDS and its deadly co-infections. Founded in 2006, the organization funds the final stages of research and development of new drugs, diagnostics and disease-prevention tools, helps produce data supporting guidelines for their use, and works to allow more affordable generic medicines to enter the marketplace in low- and middle-income countries. Hosted by the World Health Organization (WHO) in Geneva, Unitaid was established by the governments of Brazil, Chile, France, Norway and the United Kingdom.

<span class="mw-page-title-main">Extensively drug-resistant tuberculosis</span> Tuberculosis that is resistant to the most effective drugs

Extensively drug-resistant tuberculosis (XDR-TB) is a form of tuberculosis caused by bacteria that are resistant to some of the most effective anti-TB drugs. XDR-TB strains have arisen after the mismanagement of individuals with multidrug-resistant TB (MDR-TB).

<span class="mw-page-title-main">FIND, the global alliance for diagnostics</span> Swiss global health nonprofit organization

FIND is a global health non-profit based in Geneva, Switzerland. FIND functions as a product development partnership, engaging in active collaboration with over 150 partners to facilitate the development, evaluation, and implementation of diagnostic tests for poverty-related diseases. The organisation's Geneva headquarters are in Campus Biotech. Country offices are located in New Delhi, India; Cape Town, South Africa; and Hanoi, Viet Nam.

The Xpert MTB/RIF is a cartridge-based nucleic acid amplification test (NAAT) for simultaneous rapid tuberculosis diagnosis and rapid antibiotic sensitivity test. It is an automated diagnostic test that can identify Mycobacterium tuberculosis (MTB) DNA and resistance to rifampicin (RIF). It was co-developed by the laboratory of Professor David Alland at the University of Medicine and Dentistry of New Jersey (UMDNJ), Cepheid Inc. and Foundation for Innovative New Diagnostics, with additional financial support from the US National Institutes of Health (NIH).

Mark Harrington is an HIV/AIDS researcher, a staunch activist for HIV/AIDS and tuberculosis awareness, and the co-founder and policy director of the Treatment Action Group (TAG). After graduating from Harvard University in 1983, Harrington spent time exploring and did not commit to one specific career. When the AIDS epidemic became personal for Harrington, and close friends were being infected with HIV, he decided to take action and joined the group, AIDS Coalition to Unleash Power or ACT UP. As part of the Treatment and Data Committee of ACT UP, Harrington fostered relationships with government officials associated with AIDS research. Eventually differences in opinions on how to best advocate for HIV/AIDS research led to Harrington and other members of ACT UP leaving to start their own group, TAG. With TAG, Harrington was able to create influential and meaningful policy regarding HIV/AIDS research and he worked closely with the NIH, WHO, and other government organizations. Over the years Harrington has distinguished himself as an adept scientist and reputable researcher in his own right. Currently he is published in multiple scientific journals and continues to be an advocate for those with HIV and TB around the world.

Infectious diseases within American correctional settings are a concern within the public health sector. The corrections population is susceptible to infectious diseases through exposure to blood and other bodily fluids, drug injection, poor health care, prison overcrowding, demographics, security issues, lack of community support for rehabilitation programs, and high-risk behaviors. The spread of infectious diseases, such as HIV and other sexually transmitted infections, hepatitis C (HCV), hepatitis B (HBV), and tuberculosis, result largely from needle-sharing, drug use, and consensual and non-consensual sex among prisoners. HIV and hepatitis C need specific attention because of the specific public health concerns and issues they raise.

The Medicines Patent Pool (MPP) is a Unitaid-backed international organisation founded in July 2010, based in Geneva, Switzerland. Its public health driven business model aims to lower the prices of HIV, tuberculosis and hepatitis C medicines and facilitate the development of better-adapted HIV treatments through voluntary licensing and patent pooling. Its goal is to improve access to affordable and appropriate HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries (LMIC). In May 2020, the MPP become an implementing partner of the WHO's Covid-19 Technology Access Pool (C-TAP).

<span class="mw-page-title-main">Cepheid (company)</span> American molecular diagnostics company

Cepheid is an American molecular diagnostics company that is a wholly owned subsidiary of Danaher Corporation. Its systems automate traditional nucleic acid tests. The tests can be used to identify and analyze pathogens and genetic disorders. Cepheid sells clinical tests for healthcare-associated infections, infectious diseases, sexual health, oncology and genetics.

<span class="mw-page-title-main">Initiative for Medicines, Access, and Knowledge</span> Nonprofit organization

The Initiative for Medicines, Access, and Knowledge, known as I-MAK, is a U.S.-based global 501(c)(3) organization that advocates in the public interest for affordable access to medicines, and a medicines system that is more inclusive of patients and the public.

Ivy Kwan Arce is a first-generation Chinese American HIV survivor, HIV/AIDS activist and artist. She is a surviving member of the People with Aids (PWA) Health Group and was part of grassroots organizations such as the Asian Pacific Islander Coalition on HIV/AIDS (APICHA) and God's Love We Deliver. Today Kwan Arce is a longstanding activist with groups such as ACT UP and TAG.

References

  1. ↑ Harrington, Mark. Interview with Sarah Schulman and Jim Hubbard. ACTUP Oral History Project. 16 February 2005. MIX: The New York Lesbian & Gay Experimental Film Festival. 11 December 2005 <http://www.actuporalhistory.org/interviews/images/harrington.pdf Archived 2021-04-24 at the Wayback Machine >.
  2. ↑ TAG at 10: 1992 <http://www.aidsinfonyc.org/tag/tagatTen.html#1992 Archived 2007-09-28 at the Wayback Machine >.
  3. ↑ Kolata, Gina (12 September 1994). "F.D.A. Debate on Speedy Access to AIDS Drugs Is Reopening". New York Times. Retrieved 22 September 2015.
  4. ↑ TAG at 10 Timeline < "TAG at 10: 1992-2002". Archived from the original on 2007-09-28. Retrieved 2007-05-06.{{cite web}}: CS1 maint: unfit URL (link)>.
  5. ↑ TAG TB/HIV Press Release < "TAG TB/HIV Project grant from Gates Foundation". Archived from the original on 2007-07-03. Retrieved 2007-05-06.{{cite web}}: CS1 maint: unfit URL (link)>
  6. ↑ "No profiteering on COVID-19 drugs and vaccines, says MSF". Médecins Sans Frontières (MSF) International.
  7. ↑ "Covid-19: How South Africa will test for the virus". www.msn.com.
  8. ↑ "Treatment Action Group Statement on the High Price of Cepheid's Xpert Test for COVID-19". Treatment Action Group.
  9. ↑ About TAG < "About Treatment Action Group". Archived from the original on 2007-04-05. Retrieved 2007-05-06.{{cite web}}: CS1 maint: unfit URL (link)>.
  10. ↑ "August 6, 2009 Gay City News | PDF | Hate Crimes | Homosexuality". Scribd.
  11. ↑ New Yorker magazine
  12. ↑ "Why I Think How to Survive a Plague Is Going to be Huge". HuffPost. September 21, 2012.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.